Click here to view the December 2021 edition of Dates for Your Diary.
Cambridge, UK and Brussels, Belgium 16 December 2021:
Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and Bioqube Ventures (“Bioqube”), a specialist European life sciences investment firm, announced today that they have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases.
Under the terms of the collaboration, Bioqube and Metrion will advance a lead series of previously identified highly potent and selective small molecule inhibitors of the…
AMSBIO has expanded its range of custom gene editing services to complement its extensive portfolio of off-the-shelf CRISPR/Cas9 products.
A powerful technology, widely used in genome science, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) / Cas9 is a simple and efficient editing tool which allows for specific genome disruption and replacement facilitating the manipulation of specific genes with high specificity and low cell toxicity. CRISPR/Cas9 is a rapid technique that can be applied directly in embryo and is easily programmable by changing the guide sequence of the…
Cambridge UK: 15 December 2021
The PCML Group has become a Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the Partner and One Nucleus members.
Carl Dean, Engineering Director of the PCML Group ‘We are really looking forward to working with One Nucleus and its members. Our hope is that by partnering with One Nucleus, we develop a deeper understanding of the challenges faced in the development and manufacture of Life Science and Biomedical technology and share our precision engineering and manufacturing expertise with the Life…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES EXCLUSIVE COLLABORATION WITH GLOBAL TECHNOLOGY LEADER
Development of a stable liquid formulation for use within partner’s technology
Cambridge, UK, 14 December 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration.
The partner is a global technology leader, serving customers across research, clinical and applied markets. Under the terms of the agreement, Arecor will use its…
LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, presented further progress on obecabtagene autoleucel (obe-cel) in an oral presentation [Abstract 477] entitled “Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process” at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021. The Company also presented an update of obe-cel in relapsed/refractory aggressive and indolent B-Cell Non-…
AMSBIO has announced a new range of kits, media and reagents to assist in the development of cultured meat products - an exciting new area of food technology.Cultured meat, also known as synthetic, artificial or in-vitro meat, is created by harvesting animal cells that are then placed in a bioreactor and fed with nutrients to help tissue growth. The driving force behind this rapidly expanding area of food technology is that the production of cultured meat requires far fewer animals to be farmed - so that a shift to cultured meat would reduce the production of…
An independent report has been released today by Stevenage Bioscience Catalyst (SBC) that demonstrates its key role in delivering economic benefit from life sciences research and innovation in the UK.
SBC was formed in 2012 through a collaboration between the Department for Business, Energy and Industrial Strategy (BEIS), GlaxoSmithKline, Wellcome and Innovate UK. Located on the GSK Campus in Stevenage, it is home to the Cell and Gene Therapy Catapult Manufacturing Centre, LifeArc, Cytiva and around 40 thriving start-ups.
Entitled ‘Stevenage Bioscience Catalyst’s key role in delivering…
Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Rory Curtis as Vice President US Commercial Operations. The appointment represents the next phase in the Company’s expansion plans and business growth, driven by its ion channel discovery capabilities.
Rory is based in Buffalo, NY, and will be responsible for Metrion’s business development operations throughout the United States, including supporting and expanding the Company’s existing client base and leading the development of new business…
NEW YORK and LONDON, December 7, 2021—ATP (Apple Tree Partners), a leader in life sciences venture capital, today announced the launch of Adendra Therapeutics Ltd. (“Adendra”), a company that will discover and develop treatments for cancers and autoimmune diseases by applying new insights into regulation of adaptive immune responses by dendritic cells. Adendra is funded with a $53 (£40) million Series A investment from ATP and founded by ATP as a spin-out of breakthrough biology conducted at the Francis Crick Institute in London in the lab of immunologist Caetano Reis e Sousa, D.Phil., whose…